NEW YORK (GenomeWeb) – Precision Therapeutics today announced a $60 million investment and a new name, Helomics.

Helomics also named a new management team and board. The privately held firm will remain based in Pittsburgh and develop diagnostics targeting cancer. It said that it will advance proprietary technology platforms in genomics, proteomics, bioinformatics, and cellular analysis combined with a personalized reporting system for tumor profiling and predictive analytics to aid physicians in determining the most appropriate treatment options for their patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.